FTH logo

FAETH THERAPEUTICS INC

FTHNASDAQ
πŸ† #3457 by market capEarnings Mar 29US Equity
$7.88β–Ό $0.81 (βˆ’9.32%)
Market closed Β· at close
πŸ””
Track FTH
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 9.3%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$204M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
β€”
Insufficient data
No chart data available for FTH.

Trading Snapshot

Day Range
$7.84 – $9.13
52-Week Range
$7.84 – $42.14
Volume (shares)
419,108
Avg Volume (shares)
β€”
Shares Outstanding
25.8M
Next Earnings
2027-03-29

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-138.82
Dividend Yield
β€”
Dilution (1yr)
+0.3%
FTH logo

FAETH THERAPEUTICS INC

FTH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$22Mβ–Ό βˆ’29.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$20Mβ–Ό βˆ’17.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.3Mβ–² +0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7Mβ–² +$1M YoY
StockOtter Β· stockotter.space

About FAETH THERAPEUTICS INC

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.